Technical Analysis for DYAI - Dyadic International, Inc.

Grade Last Price % Change Price Change
F 5.01 -1.57% -0.08
DYAI closed down 1.57 percent on Friday, April 16, 2021, on 13 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical DYAI trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.57%
Wide Bands Range Expansion -1.57%
Oversold Stochastic Weakness -1.57%
Doji - Bullish? Reversal -1.76%
Wide Bands Range Expansion -1.76%
Oversold Stochastic Weakness -1.76%
Stochastic Buy Signal Bullish -2.53%
Wide Bands Range Expansion -2.53%
Older End-of-Day Signals for DYAI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dyadic International, Inc. Description

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV) and certain metabolites. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Natural Sciences Pharmacy Antibodies Medication Monoclonal Antibodies Vaccine Gene Expression Biopharmaceuticals Fusion Protein Healthcare System Biosimilar

Is DYAI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.98
52 Week Low 4.56
Average Volume 737,952
200-Day Moving Average 6.73
50-Day Moving Average 5.48
20-Day Moving Average 5.36
10-Day Moving Average 5.18
Average True Range 0.38
ADX 23.1
+DI 27.52
-DI 22.36
Chandelier Exit (Long, 3 ATRs ) 7.63
Chandelier Exit (Short, 3 ATRs ) 5.71
Upper Bollinger Band 6.14
Lower Bollinger Band 4.58
Percent B (%b) 0.27
BandWidth 28.95
MACD Line -0.09
MACD Signal Line -0.06
MACD Histogram -0.0258
Fundamentals Value
Market Cap 137.69 Million
Num Shares 27.5 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -19.57
Price-to-Sales 93.83
Price-to-Book 5.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.43
Resistance 3 (R3) 5.43 5.28 5.36
Resistance 2 (R2) 5.28 5.18 5.29 5.34
Resistance 1 (R1) 5.15 5.11 5.08 5.15 5.31
Pivot Point 5.00 5.00 4.97 5.01 5.00
Support 1 (S1) 4.87 4.90 4.80 4.87 4.71
Support 2 (S2) 4.72 4.83 4.73 4.68
Support 3 (S3) 4.59 4.72 4.66
Support 4 (S4) 4.59